Randomized, single-blind, crossover study to assess the pharmacokinetic and pharmacodynamic bioequivalence of CHS-1701 to pegfilgrastim in healthy subjects.John A. Glaspy, Barbara Finck, Paula G. O’Connor et al.|Journal of Clinical Oncology|2017Cited by 8
CHS-131, A Novel Once Daily Oral Treatment, Decreased Lesion Burden of Patients with Relapsing-Remitting Course of Multiple Sclerosis (RRMS) in a Randomized, Double-blind, Phase 2b, Multicenter Study (S50.002)David Weinstein, Barbara Finck, Alexey Boykо et al.|Neurology|2017Cited by 7
Pharmacokinetic and Pharmacodynamic Bioequivalence of Pegfilgrastim-cbqv Delivered via a Prefilled Autoinjector and Prefilled Syringe in Healthy Male ParticipantsHong Tang, Barbara Finck, Francesca Civoli et al.|Advances in Therapy|2023Cited by 7
SAT0162 Switching from etanercept to CHS-0214: a one year, randomized, double-blind study in patients with rheumatoid arthritisJames R. O’Dell, Barbara Finck, Alan Kivitz et al.|Annals of the Rheumatic Diseases|2017Cited by 3
OP0220 Randomized, double-blind, global clinical trial to evaluate equivalence of CHS-1420 to adalimumab in patients with psoriasis and psoriatic arthritisJames R. O’Dell, Barbara Finck, Alan Kivitz et al.|Annals of the Rheumatic Diseases|2017Cited by 3